Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Buy" from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) has received a consensus rating of "Buy" from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $30.00.

A number of equities analysts have commented on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Wedbush restated an "outperform" rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, June 13th.

Institutional Investors Weigh In On Astria Therapeutics

Institutional investors have recently modified their holdings of the business. Deutsche Bank AG raised its position in shares of Astria Therapeutics by 54.3% in the 4th quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company's stock valued at $355,000 after acquiring an additional 13,986 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Astria Therapeutics by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company's stock valued at $567,000 after purchasing an additional 7,756 shares in the last quarter. GAMMA Investing LLC raised its holdings in Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,971 shares during the period. Teacher Retirement System of Texas bought a new position in shares of Astria Therapeutics during the fourth quarter worth $91,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Astria Therapeutics during the fourth quarter worth $41,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Stock Up 6.7%

NASDAQ:ATXS traded up $0.39 during trading hours on Monday, reaching $6.20. 630,857 shares of the stock were exchanged, compared to its average volume of 387,765. The stock has a market capitalization of $349.87 million, a P/E ratio of -3.32 and a beta of 0.41. The firm has a 50 day simple moving average of $5.02 and a 200-day simple moving average of $6.09. Astria Therapeutics has a 52 week low of $3.56 and a 52 week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.10). As a group, analysts expect that Astria Therapeutics will post -1.65 earnings per share for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.